Medical Pharmacology: Chapter 8: Antiarrhythmic Drugs -- Module 3: Class II Beta-Blockers in Arrhythmia Management

Chapter 8: Antiarrhythmic Drugs — Module 3: Class II Beta-Blockers in Arrhythmia Management
Tier: 2 — Conceptual Understanding (13 questions)

1. A 64-year-old man with anterior MI three years ago (EF 36%), symptomatic peripheral arterial disease (PAD) with claudication, and persistent AF at 96 bpm at rest is being initiated on a beta-blocker for HFrEF. His cardiologist considers carvedilol versus metoprolol succinate. Which pharmacologic property of carvedilol makes it potentially advantageous in a patient with both HFrEF and PAD?

A) Carvedilol's β1-selectivity spares peripheral β2 receptors, reducing vasoconstriction in PAD-affected limbs
B) Carvedilol's renal elimination avoids hepatic first-pass metabolism that worsens peripheral circulation
C) Carvedilol's α1-adrenergic receptor blockade produces peripheral vasodilation, potentially improving limb perfusion in PAD, while its combined β-blockade provides the proven HFrEF mortality benefit
D) Carvedilol's membrane-stabilizing activity reduces vascular smooth muscle contractility in diseased peripheral arteries
E) Carvedilol's longer half-life compared to metoprolol provides more consistent peripheral vasodilation throughout the day

ANSWER: C

Rationale:

Carvedilol is unique among beta-blockers in combining non-selective β1+β2 blockade with α1-adrenergic receptor blockade. The α1-blocking property produces peripheral arterial vasodilation — potentially beneficial in PAD by reducing peripheral vascular resistance and improving distal limb perfusion. Non-selective beta-blockers without α1-blockade (propranolol, nadolol) can worsen peripheral vasoconstriction in PAD by removing β2-mediated vasodilation while leaving α1-mediated vasoconstriction intact. Carvedilol avoids this by simultaneously blocking α1. In HFrEF, carvedilol has demonstrated mortality benefit in COPERNICUS and CAPRICORN. Carvedilol is not β1-selective — option A is factually incorrect. Its elimination is hepatic (CYP2D6/CYP2C9), not renal.

2. A 58-year-old man with paroxysmal AF and preserved EF is being considered for rhythm control therapy. His cardiologist discusses sotalol versus metoprolol. Which statement correctly distinguishes sotalol from metoprolol in terms of mechanism and monitoring requirements?

A) Sotalol combines β-adrenergic blockade (Class II) with IKr blockade (Class III), prolonging the QT interval and requiring QTc monitoring and renal dose adjustment; metoprolol is a pure β1-selective blocker without QT effects or mandatory QTc monitoring
B) Sotalol is β1-selective with additional Class Ia sodium channel blockade; metoprolol is non-selective without sodium channel effects
C) Sotalol and metoprolol have identical antiarrhythmic mechanisms but sotalol requires QTc monitoring due to its renal elimination kinetics
D) Sotalol prolongs the PR interval more than metoprolol due to its dual AV nodal blockade through both β-receptors and L-type Ca2+ channels
E) Sotalol's QT prolongation is clinically irrelevant at doses used for AF rate control; monitoring is required only at antiarrhythmic doses above 320 mg daily

ANSWER: A

Rationale:

Sotalol has a dual mechanism: Class II β-adrenergic blockade and Class III IKr (hERG) blockade. The IKr blockade prolongs ventricular action potential duration and the QT interval, creating a dose-dependent risk of torsades de pointes (TdP) — particularly in the presence of hypokalemia, bradycardia, or QT-prolonging co-medications. Sotalol requires baseline QTc measurement, electrolyte normalization, in-hospital initiation for dose titration, and renal dose adjustment (contraindicated at CrCl below 40 mL/min, as it is 100% renally eliminated). Metoprolol is a pure β1-selective blocker with no IKr activity, no QT effects, and no mandatory QTc monitoring requirement. This mechanistic distinction — Class II only versus Class II+III — determines the entire monitoring and contraindication profile.

3. A 72-year-old man with HFrEF (EF 28%) and Child-Pugh class A cirrhosis (mild hepatic impairment) requires initiation of a guideline-directed beta-blocker. His creatinine clearance is 55 mL/min. Which beta-blocker and rationale is most appropriate?

A) Metoprolol succinate — CYP2D6 metabolism is unaffected by mild cirrhosis and it has the strongest trial evidence in HFrEF
B) Carvedilol — α1-blockade reduces portal hypertension, providing an additional benefit in cirrhosis
C) Propranolol — its high lipophilicity and extensive first-pass metabolism make plasma levels more predictable in hepatic disease
D) Nadolol — non-selective blockade provides superior neurohormonal suppression in HFrEF compared to β1-selective agents
E) Bisoprolol — highly β1-selective with elimination that is approximately 50% renal and 50% hepatic, making pharmacokinetics more predictable in mild hepatic impairment than agents with predominantly hepatic clearance; demonstrated mortality benefit in HFrEF in CIBIS-II (CIBIS-II: Cardiac Insufficiency Bisoprolol Study II, 1999)

ANSWER: E

Rationale:

Bisoprolol has a dual elimination route — approximately 50% renal and 50% hepatic — making it pharmacokinetically more predictable than agents with predominantly hepatic metabolism (metoprolol, carvedilol, propranolol) in patients with hepatic impairment. Its high β1-selectivity is appropriate in HFrEF. CIBIS-II randomized 2,647 patients with symptomatic HFrEF (EF 35% or less, NYHA Class III–IV) to bisoprolol or placebo and demonstrated a 34% reduction in all-cause mortality, establishing bisoprolol as one of only three agents with proven HFrEF mortality benefit. Metoprolol succinate (predominantly CYP2D6 hepatic) and carvedilol (CYP2D6/CYP2C9 hepatic) accumulate unpredictably in hepatic disease. Nadolol does not have proven HFrEF mortality benefit despite its non-selectivity.

4. A 56-year-old man presents with acute-onset tearing chest pain radiating to the back. CT angiography confirms a Stanford type B aortic dissection (descending aorta, not involving the ascending aorta). BP is 178/96 mmHg and heart rate 102 bpm. Which pharmacologic agent is the immediate priority and why?

A) IV sodium nitroprusside — direct arteriolar vasodilation reduces BP most rapidly
B) IV esmolol — reduces both heart rate and the rate of rise of aortic pressure (dP/dt), the primary mechanical force driving dissection propagation; beta-blockade is the initial priority before vasodilators
C) IV labetalol — combined α1/β-blockade reduces BP and heart rate simultaneously, making it more efficient than pure beta-blockade
D) IV nicardipine — dihydropyridine calcium channel blocker reduces BP without negative chronotropy, preserving cardiac output
E) IV metoprolol — β1-selective blockade reduces heart rate without the vasodilatory reflex tachycardia that complicates sodium nitroprusside

ANSWER: B

Rationale:

In acute aortic dissection, the primary therapeutic target is reduction of dP/dt — the rate of rise of aortic pressure — which is the primary mechanical force driving dissection propagation and the risk of aortic rupture. Beta-blockers reduce dP/dt by decreasing both heart rate and myocardial contractility. IV esmolol is the preferred initial agent because its ultra-short half-life allows precise titration to a target heart rate of 60 bpm and systolic BP below 120 mmHg, with rapid reversibility if hypotension occurs. Vasodilators such as sodium nitroprusside can be added if BP targets are not achieved with beta-blockade alone, but vasodilators must never be given without prior beta-blockade — they cause reflex tachycardia that increases dP/dt and accelerates dissection. Labetalol is an acceptable alternative to the esmolol + vasodilator combination but has a longer half-life with less precise titratability.

5. A 22-year-old woman with CPVT (RyR2 mutation confirmed) has been on nadolol 80 mg daily for three years. Despite optimal beta-blockade (resting HR 52 bpm), she continues to have breakthrough bidirectional VT during moderate exercise. An ICD has been deferred due to patient preference. Which pharmacologic adjunct is most appropriate?

A) Amiodarone — multi-channel blockade provides the most comprehensive suppression of catecholamine-driven arrhythmias
B) Metoprolol — switching to a higher-dose β1-selective agent provides more targeted cardiac β1 suppression
C) Verapamil — ICaL blockade reduces Ca2+ entry into the SR, decreasing the Ca2+ overload that triggers RyR2 leak
D) Flecainide — low-dose Class Ic agent that directly inhibits the RyR2 channel independent of adrenergic blockade, providing additive suppression of SR Ca2+ leak in CPVT refractory to beta-blockade
E) Dofetilide — IKr blockade stabilizes ventricular repolarization, reducing the triggered activity driven by DADs in CPVT

ANSWER: D

Rationale:

In CPVT refractory to optimal beta-blockade, flecainide at low doses has been shown to directly inhibit the RyR2 channel — a mechanism entirely independent of its Class Ic sodium channel blockade. This RyR2-stabilizing effect reduces pathologic SR Ca2+ leak and suppresses DAD-mediated triggered activity. Multiple case series and small trials demonstrate arrhythmia reduction with the combination of nadolol plus flecainide in refractory CPVT. This is a recognized exception to the general contraindication of Class Ic agents — in CPVT without structural heart disease, flecainide's RyR2-targeting property provides unique mechanistic benefit. Amiodarone does not target RyR2 and has significant long-term toxicity. Dofetilide addresses repolarization but not the upstream Ca2+ leak mechanism. ICD implantation remains the definitive safety net and should be reconsidered if pharmacologic adjuncts fail.

6. A 66-year-old woman with paroxysmal AF and preserved EF (55%) is on metoprolol succinate 50 mg daily for rate control. At a routine visit her heart rate is 88 bpm and her cardiologist considers adding oral verapamil for further rate control. Why is this combination problematic?

A) Verapamil induces CYP2D6 and accelerates metoprolol metabolism, reducing its effectiveness
B) Verapamil's α1-blocking property combined with metoprolol's β-blockade causes excessive peripheral vasodilation and hypotension
C) Both metoprolol and verapamil slow AV nodal conduction through different mechanisms — β-blockade and ICaL blockade respectively — and their combination carries a significant risk of high-degree AV block, severe bradycardia, and hemodynamic compromise
D) Verapamil displaces metoprolol from plasma protein binding, causing acute metoprolol toxicity
E) The combination is safe in preserved EF but contraindicated only in patients with HFrEF due to additive negative inotropy

ANSWER: C

Rationale:

Metoprolol slows AV nodal conduction by blocking β1-adrenergic receptor-mediated increases in ICaL and If, reducing nodal conduction velocity. Verapamil, a non-dihydropyridine calcium channel blocker (non-DHP CCB), directly blocks L-type Ca2+ channels (ICaL) in AV nodal cells, independently prolonging AV nodal refractoriness. These two mechanisms converge on the same nodal tissue through independent pathways, and their combination can produce additive or synergistic AV nodal suppression — manifesting as high-degree AV block, severe bradycardia, or complete heart block. IV verapamil in a patient already on a beta-blocker is particularly dangerous and has caused cardiac arrest. The combination should be avoided. If additional rate control is required beyond a single agent, the dose of the existing agent should be optimized or an electrophysiology consultation obtained.

7. A 48-year-old man with Child-Pugh class B cirrhosis and large esophageal varices on upper endoscopy is started on propranolol for primary prophylaxis of variceal hemorrhage. His cardiologist is asked whether a β1-selective agent such as metoprolol would be an acceptable substitute. What is the pharmacologic rationale for requiring a non-selective beta-blocker in this indication?

A) Non-selective beta-blockers reduce portal pressure through two complementary mechanisms: β1-blockade reduces cardiac output (decreasing portal blood flow), and β2-blockade in mesenteric splanchnic vessels causes vasoconstriction (increasing splanchnic resistance and further reducing portal inflow); β1-selective agents provide only the cardiac output component, yielding incomplete portal pressure reduction
B) Propranolol's higher lipophilicity allows greater hepatic accumulation, providing a local portal antihypertensive effect not achievable with hydrophilic agents
C) Non-selective agents block β2 receptors on hepatic stellate cells, directly reducing fibrosis progression and portal resistance
D) Propranolol inhibits hepatic CYP enzymes involved in vasoactive mediator synthesis, reducing endothelin-1 production and portal vascular tone
E) β1-selective agents accelerate portal blood flow by causing mesenteric vasodilation through unopposed β2 stimulation, worsening portal hypertension

ANSWER: A

Rationale:

Portal hypertension pharmacologic reduction requires non-selective beta-blockade for two mechanistic reasons. β1-blockade reduces heart rate and cardiac output, decreasing the volume of blood delivered to the portal system. β2-blockade in splanchnic (mesenteric) vasculature causes vasoconstriction — normally β2 stimulation produces mesenteric vasodilation, and blocking this effect increases splanchnic vascular resistance, reducing portal inflow. Non-selective agents (propranolol, nadolol) provide both components. β1-selective agents (metoprolol, atenolol) provide only the cardiac output reduction, leaving splanchnic β2-mediated vasodilation unopposed — an incomplete and less effective strategy for portal pressure reduction. Propranolol or nadolol are therefore standard of care for variceal prophylaxis; β1-selective substitution is pharmacologically inadequate.

8. A 61-year-old woman in the medical ICU with gram-negative sepsis develops AF with rapid ventricular response at 146 bpm. Her BP is 94/58 mmHg on norepinephrine at 0.15 mcg/kg/min. The intensivist considers rate control. Which statement best describes the evidence and approach for beta-blocker use in sepsis-associated AF with hemodynamic compromise?

A) Beta-blockers are absolutely contraindicated in sepsis-associated AF with hypotension — digoxin is the only safe rate control agent in this setting
B) IV amiodarone is the preferred agent for rate control in sepsis-associated AF because it can be given at low doses without hemodynamic compromise
C) Rate control should not be pursued in sepsis-associated AF — tachycardia is an appropriate compensatory response and pharmacologic rate control worsens cardiac output
D) Oral carvedilol should be initiated and titrated over 48 hours — the vasodilatory α1-blockade counteracts the vasopressor requirement
E) IV esmolol infusion has been associated with reduced mortality in sepsis-associated AF in small trials, likely through attenuation of catecholamine-driven myocardial injury; it can be cautiously titrated given its rapid reversibility, but this remains investigational and hemodynamic monitoring is essential

ANSWER: E

Rationale:

Esmolol in sepsis-associated AF is an area of active investigation. A small randomized trial demonstrated reduced mortality with esmolol infusion in septic shock patients with persistent tachycardia, hypothesized to result from attenuation of catecholamine-driven myocardial oxygen demand and prevention of arrhythmia-related hemodynamic deterioration. However, these findings are based on limited data and esmolol use in hemodynamically compromised sepsis patients remains investigational — it requires close hemodynamic monitoring and careful titration given the risk of worsening hypotension. IV amiodarone is an alternative but carries its own hemodynamic risks at loading doses. The key advantage of esmolol in this uncertain setting is its rapid reversibility — if hemodynamics worsen, discontinuation restores baseline within 20–30 minutes. Rate control targets and thresholds in this population are not firmly established by current guidelines.

9. A 19-year-old woman with long QT syndrome type 2 (LQT2) — caused by a loss-of-function hERG mutation reducing IKr (the rapid delayed rectifier K+ current) — is started on nadolol. Her parents ask why beta-blockers are less effective in LQT2 than in LQT1, and what triggers she should avoid. Which explanation is most accurate?

A) In LQT2, IKr loss-of-function reduces repolarization reserve during exercise specifically; beta-blockers are equally effective in LQT2 and LQT1 because both are triggered by physical activity
B) In LQT2, arrhythmias are characteristically triggered by auditory stimuli and sudden arousal (alarm clocks, sudden noises) in addition to emotional stress — triggers that involve adrenergic activation but less so than vigorous exercise; beta-blockers are moderately but not highly effective because not all LQT2 triggers are adrenergically mediated, and IKr loss cannot be compensated by adrenergic blockade alone
C) LQT2 arrhythmias are exclusively triggered during sleep-related bradycardia — beta-blockers worsen this by further slowing heart rate and are therefore contraindicated
D) Beta-blockers are ineffective in LQT2 because hERG channel function is regulated by intracellular Ca2+, not adrenergic tone, making the mechanism entirely non-adrenergic
E) LQT2 and LQT3 have identical trigger patterns and identical beta-blocker response profiles — the distinction is only pharmacokinetic

ANSWER: B

Rationale:

LQT2 is caused by hERG (KCNH2) loss-of-function mutations reducing IKr, one of the two major repolarization currents. Arrhythmias in LQT2 are characteristically triggered by sudden auditory stimuli (alarm clocks, doorbells, telephone ringing), emotional arousal, and sudden stress — triggers that involve adrenergic activation but less extreme sympathetic surges than vigorous exercise. Beta-blockers are moderately effective in LQT2 (reducing events by approximately 50%) but less dramatically effective than in LQT1, where a single mechanism (IKs/sympathetic activation) dominates. Patients with LQT2 should avoid sudden loud noises, consider removing alarm clocks from the bedroom, and use vibrating alerts rather than auditory ringtones. Swimming is also relatively contraindicated as in LQT1. Beta-blockers remain first-line therapy in LQT2 despite their partial efficacy.

10. A 44-year-old woman with episodic hypertension, headaches, and diaphoresis is found to have elevated 24-hour urinary catecholamines. A right adrenal mass is identified on CT scan consistent with pheochromocytoma. She develops a hypertensive crisis (BP 218/124 mmHg) with heart rate 118 bpm during the workup. A nurse suggests IV metoprolol for rate and blood pressure control. What is the critical error in this plan?

A) Metoprolol is contraindicated in pheochromocytoma because it inhibits catecholamine synthesis, paradoxically worsening the tumor's secretory activity
B) Metoprolol is appropriate for rate control but must be given at twice the standard dose to overcome the catecholamine excess
C) Metoprolol is contraindicated because its β1-selectivity is insufficient — only non-selective beta-blockers are safe in pheochromocytoma
D) Beta-blockade before alpha-blockade in pheochromocytoma is contraindicated — removing β2-mediated vasodilation while α1-mediated vasoconstriction remains unopposed will paradoxically worsen the hypertensive crisis; phentolamine (IV alpha-blocker) must be given first
E) Metoprolol is appropriate for rate control in pheochromocytoma crisis provided the dose is titrated carefully to avoid hypotension after tumor removal

ANSWER: D

Rationale:

Pheochromocytoma produces massive catecholamine excess with simultaneous intense α- and β-adrenergic stimulation. β2-adrenergic activity in peripheral vasculature produces vasodilation that partially counterbalances α1-mediated vasoconstriction. If a beta-blocker is given first, this β2-vasodilatory counterbalance is eliminated while α1-mediated vasoconstriction remains fully active — resulting in a paradoxical and potentially catastrophic worsening of the hypertensive crisis, exactly as in cocaine toxicity. The correct sequence is always alpha-blockade first (typically with phenoxybenzamine orally for scheduled surgery, or IV phentolamine for acute crisis), then beta-blockade once adequate α-blockade is established. This rule applies to all beta-blockers — selective and non-selective — and is absolute.

11. A 78-year-old man with LQT1 (KCNQ1 mutation) has been well-controlled on atenolol 50 mg daily for 12 years. His recent labs show a creatinine clearance of 28 mL/min (stage 4 CKD). He has no symptoms of arrhythmia. What adjustment is required and why?

A) No adjustment needed — atenolol's hepatic metabolism is unaffected by renal impairment
B) Switch to metoprolol succinate — hepatically metabolized agents are preferred in CKD to avoid drug accumulation
C) Reduce the atenolol dose or extend the dosing interval — atenolol is renally eliminated unchanged, and reduced creatinine clearance causes drug accumulation leading to excessive β1-blockade with bradycardia and AV block risk
D) Switch to nadolol — its higher lipophilicity provides more consistent plasma levels in CKD despite renal elimination
E) Switch to propranolol — its hepatic metabolism avoids the renal elimination problem, and its non-selectivity provides broader protection in LQT1

ANSWER: C

Rationale:

Atenolol is renally eliminated as unchanged drug — it undergoes minimal hepatic metabolism. At a creatinine clearance of 28 mL/min, atenolol clearance is substantially reduced, causing drug accumulation and progressively increasing plasma concentrations at a fixed dose. The clinical consequence is exaggerated β1-blockade: bradycardia, AV block, and hypotension. Standard dose adjustment guidelines reduce the atenolol dose by 50% when CrCl falls to 15–35 mL/min, or extend the dosing interval. Alternative strategies include switching to a hepatically metabolized beta-blocker such as metoprolol succinate or carvedilol (neither of which accumulates in CKD). In LQT1, maintaining beta-blocker coverage is essential — abrupt discontinuation risks withdrawal-triggered torsades de pointes. The dose adjustment rather than discontinuation is the correct approach.

12. A 55-year-old man with CPVT on nadolol reports no arrhythmias but complains of fatigue and mild exercise intolerance. His colleague with CPVT on propranolol reports vivid nightmares, depression, and cognitive slowing. What pharmacologic property explains the difference in CNS side effect profiles between these two non-selective beta-blockers?

A) Nadolol is hydrophilic (low lipophilicity) with minimal blood-brain barrier penetration, producing few CNS side effects; propranolol is highly lipophilic, crosses the blood-brain barrier readily, and produces significant CNS adverse effects including fatigue, depression, sleep disturbances, and vivid dreams
B) Nadolol has a shorter half-life than propranolol, producing peak-and-trough plasma levels that reduce CNS exposure
C) Nadolol selectively blocks peripheral β-receptors while propranolol has equal central and peripheral β-blockade
D) Propranolol's membrane-stabilizing activity produces CNS toxicity through direct neuronal sodium channel blockade
E) Nadolol undergoes hepatic metabolism to active CNS-inactive metabolites, while propranolol is renally eliminated and accumulates in CSF

ANSWER: A

Rationale:

Lipophilicity is the primary determinant of CNS penetration for beta-blockers. Nadolol is highly hydrophilic, distributes poorly into lipid-rich CNS tissue, and produces minimal CNS side effects. Propranolol is highly lipophilic, readily crosses the blood-brain barrier, and produces well-documented CNS adverse effects: fatigue, depression, sleep disturbance, vivid dreams, and cognitive slowing. This distinction is clinically important when selecting a beta-blocker for a patient with existing mood disorder or who performs cognitively demanding work. Hydrophilic alternatives to propranolol include nadolol, atenolol, and sotalol — all of which have substantially lower CNS penetration. In CPVT, nadolol is preferred over propranolol for both its non-selective pharmacology and its superior CNS tolerability profile.

13. A 38-year-old man with no structural heart disease on cardiac MRI presents with palpitations reproducibly occurring during vigorous exercise. An exercise stress test captures a run of polymorphic ventricular tachycardia (VT) at peak exertion that self-terminates at rest. Genetic testing is pending. Which pharmacologic agent is the most appropriate initial treatment and what is the mechanism?

A) Amiodarone — broad multi-channel antiarrhythmic coverage suppresses all forms of exercise-induced VT regardless of mechanism
B) Flecainide — Class Ic sodium channel blockade prevents exercise-induced VT through rate-dependent sodium channel suppression
C) Verapamil — some forms of exercise-induced VT originate from the left ventricular fascicles and are verapamil-sensitive; this should be tried before beta-blockers
D) Mexiletine — exercise-induced VT in young patients without structural disease is driven by INaL, which mexiletine selectively blocks
E) Beta-blockers (nadolol or metoprolol) — exercise-induced VT in the absence of structural heart disease is most commonly catecholamine-driven, arising from delayed afterdepolarizations (DADs) generated by PKA-mediated SR Ca2+ overload during adrenergic stimulation; beta-blockers interrupt this cascade at the upstream adrenergic step

ANSWER: E

Rationale:

Exercise-induced VT in patients without structural heart disease most commonly represents catecholamine-mediated triggered activity — DADs arising from PKA-mediated SR Ca2+ overload during sympathetic activation, as seen in CPVT and related DAD-driven arrhythmia syndromes. Beta-blockers are the first-line treatment, interrupting the adrenergic cascade that drives the Ca2+ overload. Genetic testing is essential to identify CPVT (RyR2 or CALSEQ2 mutations) and guide agent selection — if CPVT is confirmed, nadolol (non-selective, long half-life) is preferred. Verapamil-sensitive VT is a specific entity (idiopathic left ventricular VT, typically left posterior fascicular origin) with a characteristic right bundle branch block morphology at rest — it is not the most common presentation of exercise-induced VT and should not be the initial pharmacologic approach before a beta-blocker trial. Amiodarone and mexiletine do not target the primary catecholamine-driven mechanism.